165 related articles for article (PubMed ID: 19008642)
1. [Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA)].
Nagano N; Kawata T; Wada M
Nihon Yakurigaku Zasshi; 2008 Nov; 132(5):301-8. PubMed ID: 19008642
[No Abstract] [Full Text] [Related]
2. [Progress in the treatment of secondary hyperparathyroidism. Role of calcimimetics].
Sułowicz W
Przegl Lek; 2006; 63 Suppl 3():3-9. PubMed ID: 16898475
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients.
Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
Am J Nephrol; 2013; 37(5):405-12. PubMed ID: 23594726
[TBL] [Abstract][Full Text] [Related]
4. [Cinacalcet - an allosteric enhancer at the Ca2+-receptor].
Kebig A; Mohr K
Dtsch Med Wochenschr; 2008 Aug; 133(33):1681-3. PubMed ID: 18661462
[TBL] [Abstract][Full Text] [Related]
5. [Basic and clinical aspects of calcimimetics. Cinacalcet, effect and mechanisms of action].
Nakanishi S; Fukagawa M
Clin Calcium; 2008 Jan; 18(1):20-6. PubMed ID: 18175867
[TBL] [Abstract][Full Text] [Related]
6. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
Nagano N; Nemeth EF
J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet in hyperfunctioning parathyroid diseases.
Imanishi Y; Inaba M; Kawata T; Nishizawa Y
Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
[TBL] [Abstract][Full Text] [Related]
8. Regression of parathyroid gland swelling by treatment with cinacalcet.
Terawaki H; Nakano H; Takeguchi F; Hasegawa T; Nakayama M; Okazaki M; Hosoya T
Nephrol Dial Transplant; 2009 Feb; 24(2):690-1; author reply 691-2. PubMed ID: 18987257
[No Abstract] [Full Text] [Related]
9. Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
Ichii M; Ishimura E; Okuno S; Chou H; Kato Y; Tsuboniwa N; Nagasue K; Maekawa K; Yamakawa T; Inaba M; Nishizawa Y
Nephron Clin Pract; 2010; 115(3):c195-202. PubMed ID: 20413997
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
Nakanishi S; Fukagawa M
Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
12. Recent updates on the calcium-sensing receptor as a drug target.
Trivedi R; Mithal A; Chattopadhyay N
Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
[TBL] [Abstract][Full Text] [Related]
13. [Calcimimetics, mechanisms of action and therapeutic applications].
Ureña P; Legoupil N; de Vernejoul MC
Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
[TBL] [Abstract][Full Text] [Related]
14. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
Nagano N
Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
[TBL] [Abstract][Full Text] [Related]
15. Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride.
Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
J Clin Pathol; 2011 Sep; 64(9):756-60. PubMed ID: 21565858
[TBL] [Abstract][Full Text] [Related]
16. [Clinical application of calcimimetics].
Nishi H; Fukagawa M
Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
[TBL] [Abstract][Full Text] [Related]
17. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
Vestergaard P; Nielsen LR; Mosekilde L
Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
[TBL] [Abstract][Full Text] [Related]
18. [Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].
Hanba Y; Ooura M; Negi S; Shigematsu T
Clin Calcium; 2008 Jan; 18(1):81-8. PubMed ID: 18175876
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
20. [Parathyroid and bone. Calcimimetics and bone metabolism].
Fukumoto S
Clin Calcium; 2007 Dec; 17(12):1865-9. PubMed ID: 18057662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
